These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22398051)

  • 1. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease.
    Taxonera C; Mendoza JL; Ortega L; Pérez MI; Díaz-Rubio M
    J Crohns Colitis; 2012 May; 6(4):488-91. PubMed ID: 22398051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Severe lymphopenia in a patient with Crohn's disease].
    Monasterio C; Kreisel W; Hasselblatt P
    Internist (Berl); 2018 Aug; 59(8):857-860. PubMed ID: 29356833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB; Sagynbaeva VÉ
    Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
    Cesarini M; Angelucci E; Foglietta T; Vernia P
    J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
    Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
    [No Abstract]   [Full Text] [Related]  

  • 7. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
    McDonnell MJ; Rutherford RM; O'Regan A
    J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successfully multiple pregnancies in Crohn's disease under long-term treatment with adalimumab.
    Tursi A
    Acta Gastroenterol Belg; 2013 Jun; 76(2):264-5. PubMed ID: 23898572
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
    Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
    Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adalimumab vasculitis in a patient with Crohn's disease].
    Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
    Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
    Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
    Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 15. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
    J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 19. Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
    Willson KJ; Jacob A; Shetti MP; Bhatia R; Yee K; Osler W
    Med J Aust; 2012 Oct; 197(8):466-7. PubMed ID: 23072245
    [No Abstract]   [Full Text] [Related]  

  • 20. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
    Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.